Leadership About OcuTerra
DR:EAM Clinical Trial For Patients For Physicians
News Blog

For Patients

The DR:EAM study: A new clinical trial for eligible patients with diabetic retinopathy

 

background.jpg

DR:EAM Clinical Trial Patient Opportunity

Patients with diabetic retinopathy, especially those with moderate to severe NPDR, without diabetic macular edema (DME) or vision loss, presently face a difficult decision when it comes to treatment.

 

Patients Often face a difficult decision

 

OTT166

The DR:EAM clinical trial is evaluating OTT166 as a potential new therapeutic option for certain adults with DR, delivered in the form of an eye drop. This investigational non-invasive method of delivery presents the potential for patients to move beyond the current “watch-and-wait” approach to care.

 
 
Mask Group 2.png
In order to participate in this study, you must*: Be 18 years of age or olderHave been diagnosed with type 1 or 2 diabetes mellitusHave moderately severe to severe NPDR or mild PDRNot have received previous treatment for DR

*There are other criteria that you will need to meet before you can join this study; learn more at clinicaltrials.gov

OTT166 demonstrated tolerability data and biological activity in a Phase 1b trial conducted in patients with DR and diabetic macular edema (DME).